Targeted Assessment in High-Risk paTients With dIAbetes to ideNtify Undiagnosed Heart Failure

NARecruitingINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

December 22, 2022

Primary Completion Date

June 30, 2024

Study Completion Date

December 31, 2032

Conditions
Heart FailureDiabetes MellitusType 1 DiabetesType 2 DiabetesCardiovascular Diseases
Interventions
DIAGNOSTIC_TEST

NT-proBNP

NT-proBNP will be measured in all participants in the Investigational arm. If the level of the NT-proBNP is elevated (≥125pg/mL) participants will undergo a full cart-based transthoracic echocardiogram along with a clinical examination for signs of HF and a HF symptom assessment. Participants with HF identified will be referred to their local HF clinic for ongoing management.

Trial Locations (2)

G4 0SF

RECRUITING

Glasgow Royal Infirmary, Glasgow

G51 4TF

RECRUITING

Queen Elizabeth University Hospital, Glasgow

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

NHS Greater Glasgow and Clyde

OTHER